நச்சு விளைவுகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from நச்சு விளைவுகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In நச்சு விளைவுகள் Today - Breaking & Trending Today

Pfizer-BioNTech's COVID-19 vaccine effective and safe for use among cancer patients


Pfizer-BioNTech’s COVID-19 vaccine effective and safe for use among cancer patients
Researchers in Israel have conducted a study showing that the use of Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine appears to be safe and effective among patients with cancer.
“To our knowledge, this study is the first to prospectively characterize the serologic status, immunogenicity, and safety of the BNT162b2 vaccine in a cohort of patients with solid tumors who are receiving active anticancer therapies,” writes the team from the Rambam Health Care Campus, the Rappaport Faculty of Medicine, and the Technion-Integrated Cancer Center, in Haifa.
While the efficacy and safety profiles of COVID-19 vaccines have previously been demonstrated in phase 3 studies, the team says patients with cancer were not adequately represented in these trials. ....

Irit Ben Aharon , Sally Robertson , Rambam Health Care Campus , Cancer Center , Rappaport Faculty , Technion Integrated Cancer Center , Serologic Status , Toxic Effects , Patients Undergoing Treatment , Image Credit , சாலி ராபர்ட்சன் , புற்றுநோய் மையம் , ராப்பபோர்ட் ஆசிரிய , தொழில்நுட்பம் ஒருங்கிணைந்த புற்றுநோய் மையம் , நச்சு விளைவுகள் , படம் கடன் ,

Cancer Patients Gain Disease Protection After mRNA Vaccination


July 8, 2021 • 11:11 am CDT
(Precision Vaccinations)
The JAMA Oncology published the results from a cohort study Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer.
On July 8, 2021, this Original Investigation concluded by saying, In this cohort study of 223 cancer patients, the SARS-CoV-2 BNT162b2 vaccine (Pfizer-BioNTech, Comrinaty) appeared to be safe and achieve satisfactory serologic status.
There was a pronounced lag in antibody production compared with the rate in noncancer controls.
However, seroconversion occurred in most patients after the second vaccine dose.
Moreover, future real-world data are warranted to determine the long-term efficacy of the Pfizer-BioNTech vaccine concerning the type of anticancer treatment. ....

Israel Cancer Research Fund , Precision Vaccinations , Serologic Status , Toxic Effects , Patients Undergoing Treatment , Original Investigation , Pfizer Lecture , இஸ்ரேல் புற்றுநோய் ஆராய்ச்சி நிதி , ப்ரிஸிஶந் தடுப்பூசிகள் , நச்சு விளைவுகள் , ஒரிஜிநல் விசாரணை ,